COGT
Cogent Biosciences, Inc.
There isn't enough reported data to score COGT yet.
COGT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
COGT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
COGT PE Valuation
COGT has no meaningful PE right now: it lost money over the past year.
COGT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect COGT's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
COGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.25 | -$0.20 |
| Q2 2026 | -$2.16 | +$0.03 |
| Q1 2026 | -$2.17 | +$0.08 |
| Q4 2025 | -$2.16 | +$0.19 |
| Q3 2025 | -$2.05 | +$0.44 |
| Q2 2025 | -$2.19 | +$0.30 |
| Q1 2025 | -$2.25 | +$0.24 |
| Q4 2024 | -$2.35 | +$0.07 |
COGT is still losing money, but far less than before: $2.25 per share over the past year, against $6.55 at its worst in late 2020.
COGT Quarterly Revenue
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2020 | -18333% | N/A |
| Q2 2020 | -1402% | N/A |
| Q1 2020 | -87% | N/A |
| Q4 2019 | 15% | N/A |
COGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$80.9M | -$16.5M |
| Q2 2026 | -$77.6M | -$23M |
| Q1 2026 | -$87.3M | -$20.3M |
| Q4 2025 | -$79.9M | -$19.3M |
| Q3 2025 | -$64.4M | -$12.1M |
| Q2 2025 | -$54.7M | -$11.8M |
| Q1 2025 | -$67.1M | -$14.5M |
| Q4 2024 | -$60.7M | -$16.3M |
COGT has burned cash in almost every quarter: −$326M over the past year, against −$247M the year before.
COGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +2.1M shares |
| 1 year | +51% | +58.7M shares |
| 3 years | +145% | +102M shares |
| 5 years | +396% | +138M shares |
| Available history | +2198% | +166M shares |
COGT has 173M diluted shares, up 51% from a year ago.
COGT Net Leverage
COGT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
COGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 18.6 | Oversold |
COGT's weekly RSI is 39 (neutral) and its Stochastic is 19 (oversold).
COGT PE vs Healthcare Sector
COGT has no meaningful PE right now: it lost money over the past year.
COGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.9 | 5.6% below |
| 20 week MA | $34.7 | 16% below |
| 50 week MA | $35.6 | 18% below |
| 100 week MA | $23.3 | 25% above |
| 200 week MA | $16.5 | 77% above |
COGT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 77% above its 200-week average.
COGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.96 | $12.1 | +307% |
| 2021 | $12.1 | $8.72 | -28% |
| 2022 | $8.72 | $11.0 | +26% |
| 2023 | $11.0 | $5.88 | -46% |
| 2024 | $5.88 | $7.74 | +32% |
| 2025 | $7.74 | $38.9 | +402% |
| 2026 YTD | $38.9 | $29.1 | -25% |
COGT's yearly returns have swung widely, from +402% in 2025 to −46% in 2023. It's down 25% so far in 2026.